$ Value
—
Shares
3,000
Price
—
Filed
Feb 20
Insider
Name
Hopper Jonathan Mark
Title
Chief Medical Officer
CIK
0001626325
Roles
Transaction Details
Transaction Date
2026-02-18
Code
M
Table
Derivative
Ownership
Direct
Equity Swap
No
Shares After
3,000
Footnotes
The Restricted Stock Units (RSUs) converted to phantom stock units and are deferred under the Vericel Corporation Deferred Compensation Plan. The units will be payable only in shares of Common Stock upon the Reporting Person's elected Benefit Distribution Date. | The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 17, 2023. The remaining RSUs will vest on February 17, 2027. Upon the vesting of RSUs granted to the Reporting Person on February 17, 2023, the Reporting Person deferred the receipt of 3,000 shares of Common Stock and instead received 3,000 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan. | These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). | The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 18, 2022. | These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs. | Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. | No expiration date for this type of award. | The Fair Market Value of the vested derivative securities is $37.41 per share. | These options shall begin vesting on February 19, 2026 and shall continue to vest and become exercisable in equal quarterly installments over the course of the following four (4) year period. | These RSUs vest in four annual installments with the initial vesting of RSUs granted to the Reporting Person on February 19, 2027. The remaining RSUs will vest in annual installments on February 19, 2028, February 19, 2029, and February 19, 2030, respectively.
Filing Info
Hopper Jonathan Mark's History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2026-04-02 | VCEL | M | $38K |
| 2026-04-02 | VCEL | ▼ | $122K |
| 2026-04-02 | VCEL | M | $0 |
| 2026-02-24 | VCEL | M | — |
| 2026-02-24 | VCEL | M | $0 |
| 2026-02-24 | VCEL | F | $51K |
| 2026-02-24 | VCEL | M | — |
| 2026-02-24 | VCEL | M | $0 |
| 2026-02-24 | VCEL | F | $24K |
| 2026-02-24 | VCEL | M | — |
Other Insiders at VCEL (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
| MCLAUGHLIN KEVIN F | — | $243K | 2026-02-11 |
|
Colangelo Dominick
President and CEO
|
— | — | 2026-02-24 |
| Rubino Alan L | — | — | 2026-03-25 |
| Hagen Heidi | — | $486K | 2026-03-23 |
|
Hopper Jonathan Mark
Chief Medical Officer
|
— | $122K | 2026-04-02 |
|
Halpin Michael
Chief Operating Officer
|
— | $364K | 2026-03-02 |
|
Flynn Sean C.
Chief Legal Officer
|
— | $754K | 2026-03-02 |
|
Mara Joseph Anthony Jr
Chief Financial Officer
|
— | — | 2026-02-24 |
|
SIEGAL JONATHAN
Principal Accounting Officer
|
— | — | 2026-02-24 |